Effects of short-chain acyl-CoA dehydrogenase on cardiomyocyte apoptosis

Zhenhua Zeng,Qiuju Huang,Zhaohui Shu,Peiqing Liu,Shaorui Chen,Xuediao Pan,Linquan Zang,Sigui Zhou
DOI: https://doi.org/10.1111/jcmm.12828
2016-01-01
Journal of Cellular and Molecular Medicine
Abstract:Short-chain acyl-CoA dehydrogenase (SCAD), a key enzyme of fatty acid beta-oxidation, plays an important role in cardiac hypertrophy. However, its effect on the cardiomyocyte apoptosis remains unknown. We aimed to determine the role of SCAD in tert-butyl hydroperoxide (tBHP)-induced cardiomyocyte apoptosis. The mRNA and protein expression of SCAD were significantly down-regulated in the cardiomyocyte apoptosis model. Inhibition of SCAD with siRNA-1186 significantly decreased SCAD expression, enzyme activity and ATP content, but obviously increased the content of free fatty acids. Meanwhile, SCAD siRNA treatment triggered the same apoptosis as cardiomyocytes treated with tBHP, such as the increase in cell apoptotic rate, the activation of caspase3 and the decrease in the Bcl-2/Bax ratio, which showed that SCAD may play an important role in primary cardiomyocyte apoptosis. The changes of phosphonate AMP-activated protein kinase alpha (p-AMPK alpha) and Peroxisome proliferator-activated receptor alpha (PPAR alpha) in cardiomyocyte apoptosis were consistent with that of SCAD. Furthermore, PPAR alpha activator fenofibrate and AMPK alpha activator AICAR treatment significantly increased the expression of SCAD and inhibited cardiomyocyte apoptosis. In conclusion, for the first time our findings directly demonstrated that SCAD may be as a new target to prevent cardiomyocyte apoptosis through the AMPK/PPAR alpha/SCAD signal pathways.
What problem does this paper attempt to address?